Predementic diagnosis and biomarkers of dementia in Alzheimer's disease

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFORLENZA, O. V.
dc.contributor.authorDINIZ, B. S.
dc.contributor.authorGATTAZ, W. F.
dc.date.accessioned2023-02-09T19:59:42Z
dc.date.available2023-02-09T19:59:42Z
dc.date.issued2012
dc.description.abstractIn next decades, Alzheimer's disease (AD) will reach an epidemic status unless more effective therapeutic interventions are made available. These treatments should target the modification of specific pathological cascades that lead to neurodegeneration in AD. There is evidence of a long pre-clinical stage in AD, in which neuritic plaques and neurofibrillary tangles gradually accumulate in affected brain areas. At the earliest stages of this process, no significant cognitive or functional impairment is detected by conventional clinical methods. New technologies based on structural and functional neuroimaging, and on the biochemical analysis of cerebrospinal fluid may depict correlates of intracerebral pathology in individuals with mild, pre-dementia symptoms. These methods are commonly referred to as AD-related biomarkers. Therefore, the combination of clinical and biological information yields better diagnostic accuracy to identify individuals at high risk of AD. The relevance of this diagnosis relies on the hypothesis that pharmacological interventions with disease-modifying compounds are likely to produce clinically relevant benefits if started early enough in the continuum towards dementia. In this paper, we review the clinical characteristics of the prodromal and transitional states from normal cognitive ageing to dementia in AD. We further address recent developments in biomarker research to support the early diagnosis and prediction of dementia, and discuss the challenges and perspectives for the development of disease-modifying therapies. © 2012 by Nova Science Publishers, Inc. All rights reserved.
dc.identifier.citationForlenza, O. V.; Diniz, B. S.; Gattaz, W. F.. Predementic diagnosis and biomarkers of dementia in Alzheimer's disease. In: . RESEARCH PROGRESS IN ALZHEIMER'S DISEASE AND DEMENTIA (V): NOVA SCIENCE PUBLISHERS, INC., 2012. p.113-140.
dc.identifier.isbn9781619421929
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/51146
dc.language.isoeng
dc.publisherNOVA SCIENCE PUBLISHERS, INC.
dc.relation.ispartofRESEARCH PROGRESS IN ALZHEIMER'S DISEASE AND DEMENTIA (V)
dc.rightsrestrictedAccess
dc.rights.holderCopyright NOVA SCIENCE PUBLISHERS, INC.
dc.subjectAlzheimer's disease
dc.subjectAmyloid-β protein
dc.subjectBiomarkers
dc.subjectMild cognitive impairment
dc.subjectNeuroimaging
dc.subjectPathophysiology
dc.subjectTau protein
dc.titlePredementic diagnosis and biomarkers of dementia in Alzheimer's disease
dc.typebookPart
dc.type.categorybook chapter
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcORESTES VICENTE FORLENZA
hcfmusp.contributor.author-fmusphcBRENO SATLER DE OLIVEIRA DINIZ
hcfmusp.contributor.author-fmusphcWAGNER FARID GATTAZ
hcfmusp.description.beginpage113
hcfmusp.description.endpage140
hcfmusp.origemSCOPUS
hcfmusp.origem.scopus2-s2.0-84895207471
hcfmusp.relation.referenceAbreu, I.D., Nunes, P.V., Diniz, B.S., Forlenza, O.V., Combining functional scales and cognitive tests in screening for mild cognitive impairment at a university-based memory clinic in Brazil (2008) Rev Bras Psiquiatr, 30 (4), pp. 346-349
hcfmusp.relation.referenceAisen, P.S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., Garceau, D., A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease (2006) Neurology, 67, pp. 1757-1763
hcfmusp.relation.referenceAizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J., Mathis, C., Tsopelas, N.D., Ziolko, S.K., Houck, P.R., Frequent amyloid deposition without significant cognitive impairment among the elderly (2008) Arch Neurol, 65, pp. 1509-1517
hcfmusp.relation.referenceAlbert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7 (3), pp. 270-279
hcfmusp.relation.referenceAndreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., Blennow, K., Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice (2001) Arch Neurol, 58, pp. 373-379
hcfmusp.relation.referenceApostolova, L.G., Dinov, I.D., Dutton, R.A., Hayashi, K.M., Toga, A.W., Cummings, J.L., Thompson, P.M., 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease (2006) Brain, 129, pp. 2867-2873
hcfmusp.relation.referenceArai, H., Ishiguro, K., Ohno, H., Moriyama, M., Itoh, N., Okamura, N., Matsui, T., Kohno, H., CSF phosphorylated tau protein and mild cognitive impairment: a prospective study (2000) Exp Neurol, 166, pp. 201-203
hcfmusp.relation.referenceAssini, A., Cammarata, S., Vitali, A., Colucci, M., Giliberto, L., Borghi, R., Inglese, M.L., Dagna-Bricarelli, F., Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment (2004) Neurology, 63, pp. 828-831
hcfmusp.relation.referenceBarbosa, I., Huguet, R., Mendonça, V., Sousa, L., Neves, F., Bauer, M., Teixeira, A., Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder (2011) Eur Arch Psychiatry Clin Neurosci, 261 (2), pp. 139-143
hcfmusp.relation.referenceBlacker, D., Lee, H., Muzikansky, A., Martin, E.C., Tanzi, R., McArdle, J.J., Moss, M., Albert, M., Neuropsychological measures in normal individuals that predict subsequent cognitive decline (2007) Arch Neurol, 64, pp. 862-871
hcfmusp.relation.referenceBlasko, I., Jellinger, K., Kemmler, G., Krampla, W., Jungwirth, S., Wichart, I., Tragl, K.H., Fischer, P., Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine (2008) Neurobiol Aging, 29, pp. 1-11
hcfmusp.relation.referenceBlass, J.P., Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities (2002) Neurobiol Aging, 23, pp. 1077-1084
hcfmusp.relation.referenceBlennow, K., Hampel, H., CSF markers for incipient Alzheimer's disease (2003) Lancet Neurol, 2, pp. 605-613
hcfmusp.relation.referenceBlennow, K., Cerebrospinal fluid protein biomarkers for Alzheimer's disease (2004) NeuroRx, 1, pp. 213-225
hcfmusp.relation.referenceBlennow, K., Hampel, H., Weiner, M., Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease (2010) Nat Rev Neurol, 6 (3), pp. 131-144
hcfmusp.relation.referenceBouwman, F.H., Schoonenboom, S.N., van der Flier, W.M., van Elk, E.J., Kok, A., Barkhof, F., Blankenstein, M.A., Scheltens, P., CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment (2007) Neurobiol Aging, 28, pp. 1070-1074
hcfmusp.relation.referenceBrookmeyer, R., Gray, S., Kawas, C., Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset (1998) Am J Public Health, 88, pp. 1337-1342
hcfmusp.relation.referenceBrookmeyer, R., Gray, S., Kawas, C., Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset (1998) Am J Public Health, 88, pp. 1337-1342
hcfmusp.relation.referenceBrookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, H.M., Forecasting the global burden of Alzheimer's disease (2007) Alzheimers Dement, 3, pp. 186-191
hcfmusp.relation.referenceBruscoli, M., Lovestone, S., Is MCI really just early dementia? A systematic review of conversion studies (2004) Int Psychogeriatr, 16 (2), pp. 129-140
hcfmusp.relation.referenceBrys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R., Glodzik-Sobanska, L., Mehta, P., Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment (2009) Neurobiol Aging, 30, pp. 682-690
hcfmusp.relation.referenceBuchhave, P., Zetterberg, H., Blennow, K., Minthon, L., Janciauskiene, S., Hansson, O., Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment (2008) Neurobiology of Aging, , [ahead of print]
hcfmusp.relation.referenceBuerger, K., Ewers, M., Pirttil, T., Zinkowski, R., Alafuzoff, I., Teipel, S.J., DeBernardis, J., Soininen, H., CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease (2006) Brain, 129, pp. 3035-3041
hcfmusp.relation.referenceBurton, C.L., Strauss, E., Bunce, D., Hunter, M.A., Hultsch, D.F., Functional abilities in older adults with mild cognitive impairment (2009) Gerontology, 55 (5), pp. 570-581
hcfmusp.relation.referenceBusatto, G.F., Diniz, B.S., Zanetti, M.V., Voxel-based morphometry in Alzheimer's disease (2008) Expert Rev Neurother, 8, pp. 1691-1702
hcfmusp.relation.referenceBusse, A., Hansel, A., Gühne, U., Angermeyer, M.C., Riedel-Heller, S.G., Mild cognitive impairment: long-term course of four clinical subtypes (2006) Neurology, 67, pp. 2176-2185
hcfmusp.relation.referenceCaroli, A., Frisoni, G., the Alzheimer's Disease Neuroimaging I. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort (2010) Neurobiol Aging, 31 (8), pp. 1263-1274
hcfmusp.relation.referenceChetelat, G., Desgranges, B., de la Sayette, V., Viader, F., Eustache, F., Baron, J.C., Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? (2003) Neurology, 60 (8), pp. 1374-1377
hcfmusp.relation.referenceChetelat, G., Landeau, B., Eustache, F., Mezenge, F., Viader, F., de la Sayette, V., Desgranges, B., Baron, J.C., Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study (2005) NeuroImage, 27, pp. 934-946
hcfmusp.relation.referenceChetelat, G., Eustache, F., Viader, F., De La Sayette, V., Pölerin, A., Mäzenge, F., Hannequin, D., Desgranges, B., FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment (2005) Neurocase, 11 (1), pp. 14-25
hcfmusp.relation.referenceCitron, M., Alzheimer's disease: strategies for disease modification (2010) Nat Rev Drug Discov, 9, pp. 387-398
hcfmusp.relation.referenceClark, C., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J., Weitlauf, S.L., Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? (2003) Arch Neurol, 60, pp. 1696-1702
hcfmusp.relation.referenceCunningham, C., Campion, S., Lunnon, K., Murray, C.L., Woods, J.F., Deacon, R.M., Rawlins, J.N., Perry, V.H., Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease (2009) Biol Psychiatry, 65, pp. 304-312
hcfmusp.relation.referenceDavatzikos, C., Xu, F., An, Y., Fan, Y., Resnick, S.M., Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index (2009) Brain, 132, pp. 2026-2035
hcfmusp.relation.referencede Leon, M.J., Convit, A., Wolf, O.T., Tarshish, C.Y., DeSanti, S., Rusinek, H., Tsui, W., Fowler, J., Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET) (2001) Proc Natl Acad Sci USA, 98 (19), pp. 10966-10971
hcfmusp.relation.referenceDiniz, B., Pinto, J., Forlenza, O.V., Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature (2008) World J Biol Psychiatry, 9 (3), pp. 172-182
hcfmusp.relation.referenceDiniz, B.S., Nunes, P.V., Yassuda, M.S., Forlenza, O., Diagnosis of mild cognitive impairment revisited after one year. Preliminary results of a prospective study (2009) Dement Geriatr Cogn Disord, 27, pp. 224-231
hcfmusp.relation.referenceDiniz, B.S., Pinto, J.A., Gonzaga, M.L., Guimarães, F.M., Gattaz, W.F., Forlenza, O.V., To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease (2009) Eur Arch Psychiatry Clin Neurosci, 259, pp. 248-256
hcfmusp.relation.referenceDiniz, B.S., Teixeira, A.L., Talib, L.L., Mendonça, V.A., Gattaz, W.F., Forlenza, O.V., Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression (2010) World J Biol Psychiatry, 11 (3), pp. 550-555
hcfmusp.relation.referenceDrzezga, A., Grimmer, T., Riemenschneider, M., Lautenschlager, N., Siebner, H., Alexopoulus, P., Minoshima, S., Kurz, A., Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET (2005) J Nucl Med, 46 (10), pp. 1625-1632
hcfmusp.relation.referenceDubois, B., Feldman, H.H., Jacova, C., Dekosky, S., Barberger-Gateau, P., Cummings, J., Delacourte, A., Jicha, G., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria (2007) Lancet Neurol, 6, pp. 734-746
hcfmusp.relation.referenceEdison, P., Archer, H.A., Hinz, R., Hammers, A., Pavese, N., Tai, Y.F., Hotton, G., Brooks, D.J., Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study (2007) Neurology, 68, pp. 501-508
hcfmusp.relation.referenceElias, M.F., Beiser, A., Wolf, P.A., Au, R., White, R.F., D'Agostino, R.B., The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort (2000) Arch Neurol, 57, pp. 808-813
hcfmusp.relation.referenceFagan, A.M., Mintun, M.A., Mach, R.H., Lee, S.Y., Dence, C.S., Shah, A.R., LaRossa, G.N., Holtzman, D.M., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans (2006) Ann Neurol, 59 (3), pp. 512-519
hcfmusp.relation.referenceFagan, A., Roe, C.M., Xiong, C., Mintun, M.A., Morris, J., Holtzman, D., Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults (2007) Arch Neurol, 64, pp. 343-349
hcfmusp.relation.referenceFagan, A.M., Mintun, M.A., Shah, A.R., Aldea, P., Roe, C.M., Mach, R.H., Marcus, D., Holtzman, D.M., Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease (2009) EMBO Mol Med, 1 (8-9), pp. 371-380
hcfmusp.relation.referenceFeldman, H.H., Ferris, S., Winblad, B., Sfikas, N., Mancione, L., He, Y., Tekin, S., del Ser, T., Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study (2007) Lancet Neurol, 6, pp. 501-512
hcfmusp.relation.referenceFellgiebel, A., Siessmeier, T., Scheurich, A., Winterer, G., Bartenstein, P., Schmidt, L.G., Möller, M.J., Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment (2004) BPS, 56, pp. 279-283
hcfmusp.relation.referenceFerreira, L.K., Diniz, B.S., Forlenza, O.V., Busatto, G.F., Zanetti, M.V., Neurostructural predictors of Alzheimer's disease: A meta-analysis of VBM studies (2001) Neurobiol Aging, , [epub ahead of print]
hcfmusp.relation.referenceFischer, P., Jungwirth, S., Zehetmayer, S., Weiss-gram, S., Hoenigschnabl, S., Gelpi, E., Krampla, W., Tragl, K.H., Conversion of subtypes of mild cognitive impairment to Alzheimer dementia (2007) Neurology, 68, pp. 288-291
hcfmusp.relation.referenceFjell, A.M., Walhovd, K.B., Fennema-Notestine, C., McEvoy, L.K., Hagler, D.J., Holland, D., Blennow, K., Dale, A.M., Alzheimer's Disease Neuroimaging Initiative. Brain atrophy in healthy aging is related to CSF levels of Aβ1-42 (2010) Cereb Cortex, 20 (9), pp. 2069-2079
hcfmusp.relation.referenceForlenza, O.V., Chiu, E., Mild cognitive impairment: a concept ready to move on? (2008) Cur Opin Psychiatry, 21, pp. 529-532
hcfmusp.relation.referenceForlenza, O.V., Diniz, B.S., Nunes, P.V., Memoria, C.M., Yassuda, M.S., Gattaz, W.F., Diagnostic transitions in mild cognitive impairment subtypes (2009) Int Psychogeriatr, 21 (6), pp. 1088-1095
hcfmusp.relation.referenceForlenza, O.V., Diniz, B.S., Talib, L.L., Mendonca, V.A., Ojopi, E.B., Gattaz, W.F., Teixeira, A.L., Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment (2009) Dement Geriatr Cogn Disord, 28 (6), pp. 507-512
hcfmusp.relation.referenceForlenza, O.V., Diniz, B.S., Talib, L.L., Radanovic, M., Yassuda, M.S., Ojopi, E.B., Gattaz, W.F., Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment (2010) Rev Bras Psiquiatr, 32 (3), pp. 216-222
hcfmusp.relation.referenceForlenza, O.V., Diniz, B.S., Teixeira, A.L., Ojopi, E.B., Talib, L.L., Mendonca, V.A., Izzo, G., Gattaz, W.F., Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment (2010) World J Biol Psychiatry, 11 (6), pp. 774-780
hcfmusp.relation.referenceForlenza, O.V., Torres, C.A., Talib, L.L., de Paula, V.R., Joaquim, H.G., Diniz, B.S., Gattaz, B.S., Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease (2010) J Psychiatr Res, 45 (2), pp. 220-224
hcfmusp.relation.referenceForlenza, O.V., Diniz, B.S., Radanovic, M., Santos, F.S., Talib, L.L., Gattaz, W.F., Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial (2011) Br J Psychiatry, 198 (5), pp. 351-356
hcfmusp.relation.referenceForsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Nordberg, A., PET imaging of amyloid deposition in patients with mild cognitive impairment (2008) Neurobiol Aging, 29, pp. 1456-1465
hcfmusp.relation.referenceFrank, R.A., Galasko, D., Hampel, H., Hardy, J., de Leon, M.J., Mehta, P.D., Rogers, J., Trojanowski, J.Q., National Institute on Aging Biological Markers Working G. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group
hcfmusp.relation.referenceNIA initiative on neuroimaging in Alzheimer's disease (2003) Neurobiol Aging, 24, pp. 521-536
hcfmusp.relation.referenceGomez-Isla, T., Blesa, R., Boada, M., Clarimen, J., del Ser, T., Domenech, G., Ferro, J.M., Martinez-Lage, J.M., A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study (2008) Alzheimer Dis Assoc Disord, 22, pp. 21-29
hcfmusp.relation.referenceGraff-Radford, N.R., Crook, J.E., Lucas, J., Boeve, B.F., Knopman, D.S., Ivnik, R.J., Smith, G.E., Younkin, S.G., Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease (2007) Arch Neurol, 64 (3), pp. 354-362
hcfmusp.relation.referenceGrassi-Oliveira, R., Stein, L.M., Lopes, R.P., Teixeira, A.L., Bauer, M.E., Low plasma brain-derived neurotrophic factor and childhood physical neglect are associated with verbal memory impairment in major depression--a preliminary report (2008) Biol Psychiatry, 64, pp. 281-285
hcfmusp.relation.referenceGrassi-Oliveira, R., Brietzke, E., Pezzi, J., Lopes, R., Teixeira, A., Bauer, M., Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder (2009) Psychiatry Clin Neurosci, 63, pp. 202-208. , 19175760
hcfmusp.relation.referenceHämäläinen, A., Tervo, S., Grau-Olivares, M., Niskanen, E., Pennanen, C., Huuskonen, J., Kivipelto, M., Vanhanen, M., Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment (2007) NeuroImage, 37, pp. 1122-1131
hcfmusp.relation.referenceHampel, H., Teipel, S.J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Farlow, M., Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment (2004) Mol Psychiatry, 9, pp. 705-710
hcfmusp.relation.referenceHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., Minthon, L., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study (2006) Lancet Neurol, 5 (3), pp. 228-234
hcfmusp.relation.referenceHansson, O., Buchhave, P., Zetterberg, H., Blennow, K., Minthon, L., Warkentin, S., Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease (2009) Neurobiol Aging, 30, pp. 165-173
hcfmusp.relation.referenceHansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andreasson, U., Londos, E., Wallin, A., Blennow, K., Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment (2010) Neurobiol Aging, 31 (3), pp. 357-367
hcfmusp.relation.referenceHashimoto, R., Hirata, Y., Asada, T., Yamashita, F., Nemoto, K., Mori, T., Moriguchi, Y., Ohnishi, T., Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease (2009) Genes Brain Behav, 8 (1), pp. 43-52
hcfmusp.relation.referenceHerholz, K., Salmon, E., Perani, D., Baron, J.C., Holthoff, V., Frölich, L., Schönknecht, P., Heiss, W.D., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET (2002) Neuroimage, 17 (1), pp. 302-316
hcfmusp.relation.referenceHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R.W., Neal, J.W., Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial (2008) Lancet, 372, pp. 216-223
hcfmusp.relation.referenceHooper, C., Killick, R., Lovestone, S., The GSK3 hypothesis of Alzheimer's disease (2008) J Neurochem, 104, pp. 1433-1439
hcfmusp.relation.referenceHye, A., Kerr, F., Archer, N., Foy, C., Poppe, M., Brown, R., Hamilton, G., Lovestone, S., Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease (2005) Neurosci Lett, 373, pp. 1-4
hcfmusp.relation.referenceJack, C., Lowe, V., Weigand, S., Wiste, H., Senjem, M., Knopman, D., Shiung, M., Kemp, B., Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease (2009) Brain, 132 (5), pp. 1355-1365
hcfmusp.relation.referenceJack, C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010) Lancet Neurol, 9 (1), pp. 119-128
hcfmusp.relation.referenceJefferson, A.L., Byerly, L.K., Vanderhill, S., Lambe, S., Wong, S., Ozonoff, A., Karlawish, J.H., Characterization of activities of daily living in individuals with mild cognitive impairment (2008) Am J Geriatr Psychiatry, 16 (5), pp. 375-383
hcfmusp.relation.referenceJosephs, K.A., Whitwell, J.L., Ahmed, Z., Shiung, M.M., Weigand, S.D., Knopman, D.S., Boeve, B.F., Jack Jr., C.R., Beta-amyloid burden is not associated with rates of brain atrophy (2008) Ann Neurol, 63 (2), pp. 204-212
hcfmusp.relation.referenceJorm, A.F., Assessment of cognitive impairment and dementia using informant report (1996) Clin Psychol Rev, 16, pp. 51-73
hcfmusp.relation.referenceJovicich, J., Czanner, S., Han, X., Salat, D., van der Kouwe, A., Quinn, B., Pacheco, J., Fischl, B., MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes. Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths (2009) Neuroimage, 46 (1), pp. 177-192
hcfmusp.relation.referenceKemppainen, N.M., Aalto, S., Wilson, I.A., Nagren, K., Helin, S., Brack, A., Oikonen, V., Viitanen, M., PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment (2007) Neurology, 68, pp. 1603-1606
hcfmusp.relation.referenceKim, K.R., Lee, K.S., Cheong, H.K., Eom, J.S., Oh, B.H., Hong, C.H., Characteristic profiles of instrumental activities of daily living in different subtypes of mild cognitive impairment (2009) Dement Geriatr Cogn Disord, 27 (3), pp. 278-285
hcfmusp.relation.referenceKlunk, W., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergström, M., Estrada, S., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B (2004) Ann Neurol, 55, pp. 306-319
hcfmusp.relation.referenceLewczuk, P., Beck, G., Ganslandt, O., Esselmann, H., Deisenhammer, F., Regeniter, A., Petereit, H.F., Oschmann, P., International quality control survey of neurochemical dementia diagnostics (2006) Neurosci Lett, 409, pp. 1-4
hcfmusp.relation.referenceLoewenstein, D.A., Acevedo, A., Agron, J., Duara, R., Stability of neurocognitive impairment in different subtypes of mild cognitive impairment (2007) Dement Geriatr Cogn Disord, 23, pp. 82-86
hcfmusp.relation.referenceLopez, O.L., Kuller, L.H., Mehta, P.D., Becker, J.T., Gach, H.M., Sweet, R.A., Chang, Y.F., DeKosky, S.T., Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study (2008) Neurology, 70 (19), pp. 1664-1671
hcfmusp.relation.referenceMaruyama, M., Arai, H., Sugita, M., Tanji, H., Higuchi, M., Okamura, N., Matsui, T., Yoshida, H., Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease (2001) Exp Neurol, 172, pp. 433-436
hcfmusp.relation.referenceMathis, C., Wang, Y., Holt, D.P., Huang, G.F., Debnath, M.L., Klunk, W., Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents (2003) J Med Chem, 46, pp. 2740-2754
hcfmusp.relation.referenceMattson, M.P., Pathways towards and away from Alzheimer's disease (2004) Nature, 430, pp. 631-639
hcfmusp.relation.referenceMattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.K., Ewers, M., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment (2009) JAMA, 302, pp. 385-393
hcfmusp.relation.referenceMattsson, N., Blennow, K., Zetterberg, H., Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall (2010) Clin Chem lab Med, 48, pp. 603-607
hcfmusp.relation.referenceMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology, 34 (7), pp. 939-944
hcfmusp.relation.referenceMielke, R., Pietrzyk, U., Jacobs, A., Fink, G.R., Ichimiya, A., Kessler, J., Herholz, K., Heiss, W.D., HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern (1994) Eur J Nucl Med, 21 (10), pp. 1052-1060
hcfmusp.relation.referenceMitchell, A., Shiri-Feshki, M., Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies (2009) Acta Psychiatr Scand, 119 (4), pp. 252-265
hcfmusp.relation.referenceMorris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., Fagan, A.M., Mintun, M.A., Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease (2009) Arch Neurol, 66 (12), pp. 1469-1475
hcfmusp.relation.referenceMosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., Salmon, E., Pupi, A., MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET (2004) Neurology, 63 (12), pp. 2332-2340
hcfmusp.relation.referenceMosconi, L., Tsui, W.H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E.M., de Leon, M.J., Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias (2008) J Nucl Med, 49 (3), pp. 390-398
hcfmusp.relation.referenceMrak, R.E., Neuropathology and the Neuroinflammation Idea (2009) J Alzheimer Dis, 18 (3), pp. 473-481
hcfmusp.relation.referenceNobili, F., Salmaso, D., Morbelli, S., Girtler, N., Piccardo, A., Brugnolo, A., Dessi, B., Pagani, M., Principal component analysis of FDG PET in amnestic MCI (2008) Eur J Nucl Med Mol Imaging, 35 (12), pp. 2191-2202
hcfmusp.relation.referenceNordlund, A., Rolstad, S., Klang, O., Lind, K., Pedersen, M., Blennow, K., Edman, A., Wallin, A., Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI (2008) JINS, 14, pp. 582-590
hcfmusp.relation.referenceOkello, A., Koivunen, J., Edison, P., Archer, H.A., Turkheimer, F.E., Nagren, K., Bullock, R., Brooks, D.J., Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study (2009) Neurology, 73, pp. 754-760
hcfmusp.relation.referencePadovani, A., Borroni, B., Colciaghi, F., Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease (2002) Arch Neurol, 59, pp. 71-75
hcfmusp.relation.referencePadovani, A., Pastorino, L., Borroni, B., Pettenati, C., Cottini, E., Agosti, C., Lenzi, G.L., Di Luca, M., Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD (2001) Neurology, 57, pp. 2243-2248
hcfmusp.relation.referencePalmer, K., Wang, H.X., Bäckman, L., Winblad, B., Fratiglioni, L., Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project (2002) Am J Psychiatry, 159, pp. 436-442
hcfmusp.relation.referenceParnetti, L., Lanari, A., Saggese, E., Spaccatini, C., Gallai, V., Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice (2003) Neurol Sci, 24, pp. 199-200
hcfmusp.relation.referenceParnetti, L., Lanari, A., Silvestrelli, G., Saggese, E., Reboldi, P., Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers (2006) Mech Ageing Dev, 127, pp. 129-132
hcfmusp.relation.referenceParra, M.A., Abrahams, S., Fabi, K., Logie, R., Luzzi, S., Della Sala, S., Short term memory binding deficits in Alzheimer's Disease (2009) Brain, 132, pp. 1057-1066
hcfmusp.relation.referencePeng, S., Garzon, D.J., Marchese, M., Klein, W., Ginsberg, S.D., Francis, B.M., Mount, H.T., Fahnestock, M., Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease (2009) J Neurosci, 29, pp. 9321-9329
hcfmusp.relation.referencePeng, S., Wuu, J., Mufson, E.J., Fahnestock, M., Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease (2005) J Neurochem, 93, pp. 1412-1421
hcfmusp.relation.referencePereira, F.S., Oliveira, A.M., Diniz, B.S., Forlenza, O.V., Yassuda, M.S., Cross-cultural adaptation, reliability and validity of the DAFS-R in a sample of Brazilian older adults (2010) Arch Clin Neuropsychol, 25, pp. 335-343
hcfmusp.relation.referencePereira, F.S., Yassuda, M.S., Oliveira, A.M., Diniz, B.S., Radanovic, M., Talib, L.L., Gattaz, W.F., Forlenza, O.V., Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement (2010) J Int Neuropsychol Soc, 16, pp. 297-305
hcfmusp.relation.referencePereira, F.S., Yassuda, M.S., Oliveira, A.M., Forlenza, O.V., Executive dysfunction correlates with impaired functional status in older adults with varying degrees of cognitive impairment (2008) Int Psychogeriatr, 20, pp. 1104-1115
hcfmusp.relation.referencePeres, K., Helmer, C., Amieva, H., Orgogozo, J., Rouch, I., Dartigues, J., Barberger-Gateau, P., Natural History of Decline in Instrumental Activities of Daily Living Performance over the 10 Years Preceding the Clinical Diagnosis of Dementia: A Prospective Population-Based Study (2008) J Am Geriatr Soc, 56 (1), pp. 37-44
hcfmusp.relation.referencePetersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., Kokmen, E., Mild cognitive impairment: clinical characterization and outcome (1999) Arch Neurol, 56 (3), pp. 303-308
hcfmusp.relation.referencePetersen, R.C., Stevens, J.C., Ganguli, M., Tangalos, E.G., Cummings, J.L., DeKosky, S.T., Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001) Neurology, 56, pp. 1133-1142
hcfmusp.relation.referencePetersen, R.C., Mild cognitive impairment as a diagnostic entity (2004) J Intern Med, 256, pp. 183-194
hcfmusp.relation.referencePetersen, R.C., Thomas, R.G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Levey, A., Vitamin E and donepezil for the treatment of mild cognitive impairment (2005) New Engl J Med, 352, pp. 2379-2388
hcfmusp.relation.referencePetersen, R.C., Knopman, D.S., MCI is a clinically useful concept (2006) Int Psychogeriatr, 18, pp. 314-394
hcfmusp.relation.referencePetrie, E.C., Cross, D.J., Galasko, D., Schellenberg, G.D., Raskind, M.A., Peskind, E.R., Minoshima, S., Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings (2009) Arch Neurol, 66, pp. 632-637
hcfmusp.relation.referenceReiber, H., Dynamics of brain-derived proteins in cerebrospinal fluid (2001) Clin Chim Acta, pp. 310173-310186
hcfmusp.relation.referenceReiman, E.M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Langbaum, J.B., Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease (2009) Proc Natl Acad Sci USA, 106, pp. 6820-6825
hcfmusp.relation.referenceResnick, S.M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D.P., Dannals, R.F., Ferrucci, L., Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB (2010) Neurology, 74, pp. 807-815
hcfmusp.relation.referenceRiemenschneider, M., Lautenschlager, N., Wagenpfeil, S., Diehl, J., Drzezga, A., Kurz, A., Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment (2002) Arch Neurol, 59, pp. 1729-1734
hcfmusp.relation.referenceRidha, B.H., Barnes, J., Bartlett, J.W., Godbolt, A., Pepple, T., Rossor, M.N., Fox, N.C., Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study (2006) Lancet Neurol, 5 (10), pp. 828-834
hcfmusp.relation.referenceRowe, C.C., Ackerman, U., Browne, W., Mulligan, R., Pike, K.L., O'Keefe, G., Tochon-Danguy, H., Jones, G., Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism (2008) Lancet Neurol, 7, pp. 129-135
hcfmusp.relation.referenceRozzini, L., Chilovi, B.V., Conti, M., Bertoletti, E., Delrio, I., Trabucchi, M., Padovani, A., Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration (2007) Int J Geriatr Psychiatry, 22, pp. 1217-1222
hcfmusp.relation.referenceSalloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., Sabbagh, M., van Dyck, C.H., A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease (2009) Neurology, 73, pp. 2061-2070
hcfmusp.relation.referenceScalzo, P., Kümmer, A., Bretas, T.L., Cardoso, F., Teixeira, A.L., Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease (2010) J Neurol, 257 (4), pp. 540-545
hcfmusp.relation.referenceSeo, S.W., Im, K., Lee, J.M., Kim, Y.H., Kim, S.T., Kim, S.Y., Yang, D.W., Na, D.L., Cortical thickness in single- versus multiple-domain amnestic mild cognitive impairment (2007) NeuroImage, 36, pp. 289-297
hcfmusp.relation.referenceShaw, L., Vanderstichele, H., Knapik-Czajka, M., Clark, C., Aisen, P., Petersen, R., Blennow, K., Lewczuk, P., Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects (2009) Ann Neurol, 65 (4), pp. 403-413
hcfmusp.relation.referenceSingh, V., Chertkow, H., Lerch, J.P., Evans, A.C., Dorr, A.E., Kabani, N.J., Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease (2006) Brain, 129, pp. 2885-2893
hcfmusp.relation.referenceSmall, B.J., Fratiglioni, L., Viitanen, M., Winblad, B., Bäckman, L., The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample (2000) Arch Neurol, 57, pp. 839-844
hcfmusp.relation.referenceSmall, G.W., Kepe, V., Ercoli, L.M., Siddarth, P., Bookheimer, S.Y., Miller, K.J., Lavretsky, H., Vinters, H., PET of brain amyloid and tau in mild cognitive impairment (2006) New Engl J Med, 355, pp. 2652-2663
hcfmusp.relation.referenceStephan, B.C., Matthews, F.E., McKeith, I.G., Bond, J., Brayne, C., Medical Research Council Cognitive Function and Aging Study. Early cognitive change in the general population: how do different definitions work? (2007) J Am Geriatr Soc, 55 (10), pp. 1534-1540
hcfmusp.relation.referenceStomrud, E., Hansson, O., Blennow, K., Minthon, L., Londos, E., Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly (2007) Dement Geriatr Cogn Disord, 24 (2), pp. 118-124
hcfmusp.relation.referenceSundelöf, J., Giedraitis, V., Irizarry, M.C., Sundström, J., Ingelsson, E., Rönnemaa, E., Arnlöv, J., Basun, H., Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study (2008) Arch Neurol, 65, pp. 256-263
hcfmusp.relation.referenceSunderland, T., Linker, G., Mirza, N., Putnam, K.T., Friedman, D.L., Kimmel, L.H., Bergeson, J., Cohen, R.M., Decreased beta-amyloid1 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease (2003) JAMA, 289 (16), pp. 2094-2103
hcfmusp.relation.referenceSwerdlow, R.H., Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? (2007) Neurobiol Aging, 28, pp. 1465-1480
hcfmusp.relation.referenceSwerdlow, R.H., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis: an update (2009) Exp Neurol, 218, pp. 308-315
hcfmusp.relation.referenceTabert, M.H., Albert, S.M., Borukhova-Milov, L., Camacho, Y., Pelton, G., Liu, X., Stern, Y., Devanand, D.P., Functional deficits in patients with mild cognitive impairment: prediction of AD (2002) Neurology, 58, pp. 758-764
hcfmusp.relation.referenceTan, Z.S., Beiser, A.S., Vasan, R.S., Roubenoff, R., Dinarello, C.A., Harris, T.B., Benjamin, E.J., Wolf, P.A., Inflammatory markers and the risk of Alzheimer disease: the Framingham Study (2007) Neurology, 68, pp. 1902-1908
hcfmusp.relation.referenceTang, K., Hynan, L.S., Baskin, F., Rosenberg, R.N., Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease (2006) J Neurol Sci, 240, pp. 53-58
hcfmusp.relation.referenceTapia-Arancibia, L., Aliaga, E., Silhol, M., Arancibia, S., New insights into b
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication5d22f916-9e62-48bf-99aa-65b7cb87cb46
relation.isAuthorOfPublicationa7b3531c-48ec-4ff4-93d2-772a94af0bbe
relation.isAuthorOfPublication125dcc9f-a05a-42fd-ab1d-b6db35d2616b
relation.isAuthorOfPublication.latestForDiscovery5d22f916-9e62-48bf-99aa-65b7cb87cb46
Arquivos
Coleções
Livros e Capítulos de Livros - FM/MPS
Livros e Capítulos de Livros - LIM/27